Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Net Cash Flow: 2010-2025

Historic Net Cash Flow for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $2.9 million.

  • OptimizeRx's Net Cash Flow rose 15141.39% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 4530.95%. This contributed to the annual value of -$472000.0 for FY2024, which is 8916.69% up from last year.
  • OptimizeRx's Net Cash Flow amounted to $2.9 million in Q3 2025, which was up 15141.39% from $12000.0 recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Net Cash Flow registered a high of $71.8 million during Q1 2021, and its lowest value of -$46.1 million during Q3 2022.
  • Its 5-year average for Net Cash Flow is $473784.7, with a median of $115000.0 in 2023.
  • As far as peak fluctuations go, OptimizeRx's Net Cash Flow skyrocketed by 207006.82% in 2021, and later plummeted by 606858.1% in 2022.
  • OptimizeRx's Net Cash Flow (Quarter) stood at -$374808.0 in 2021, then plummeted by 6068.58% to -$23.1 million in 2022, then soared by 117.0% to $3.9 million in 2023, then crashed by 169.87% to -$2.7 million in 2024, then soared by 206.85% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $12000.0 for Q2 2025, and $3.2 million during Q1 2025.